Advanced search

Find pages with...
Then narrow your results by...

About 77 search results

Archived – Merck Sharp & Dohme (MSD) Announces Voluntary Worldwide Withdrawal of VIOXX® (Rofecoxib) – Merck Frosst Canada Ltd

Jun 5, 2013 ... attack and stroke, beginning after 18 months of treatment in the patients taking VIOXX® compared to those taking placebo. The results for the first 18 months of the APPROVe study did not show any increased risk of confirmed CV events on VIOXX®, and in this respect are similar to the results of two placebo-controlled studies described in the current labeling

Archived – Medication Errors Involving REMINYL and AMARYL® – Janssen-Ortho Inc. and Aventis Pharma Inc.

... brochure for the medication where available from your physician; asking your pharmacist to double-check that you have received the right medication; reading any package inserts that accompany your prescriptions. The Companies are aware of 36 reports, of which 12 were confirmed, of prescriptions that were either incorrectly written, interpreted, labeled or filled

Archived – Serious Risk of Infection From Ultrasound and Medical Gels – Revision

... deficiencies: for example, gel containers are placed in a warming device, without a cap and for extended periods of time, refillable squeeze bottles are not cleaned between refills, non-sterile gels labelled for external use only are used on mucous membranes or during invasive procedures like biopsies. In order to minimize the health risks associated with the use

Archived – Obligations of Pharmacists under the Food and Drugs Act and Food and Drug Regulations

..." is defined in C.01A.001 of the Food and Drug Regulations as to sell any drug listed in Schedule C or D to the Act or in Schedule F to the Regulations, a controlled drug as defined in G.01.001(1), or a narcotic as defined in the Narcotic Control Regulations, other than at retail sale, where the seller's name does not appear on the label of the drug. C.01A.004. (1

Archived - Health Canada warns consumers not to use the dietary supplement MdMt due to potentially serious health risks

... Canada received one case report of severe liver toxicity associated with the use of another product containing methyl-1-testosterone. Methyl-1-testosterone and methyldienolone may also be labelled as 17alpha methyl-17beta-hydroxy-andros1-ene-3-one and 17a-methyl-17beta-hydroxyestra-4,9(10)dien-3-one, respectively. MdMt contains both methyl-1-testosterone

Recall of one lot of Rofact (rifampin) 300 mg due to labelling error - For Health Professionals

... request alternate formats by contacting us. Recall of one lot of Rofact (rifampin) 300 mg due to labelling error - For Health Professionals Report a Concern Starting date: May 15, 2009 Posting date: May 21, 2009 Type of communication: Dear Healthcare Professional Letter Subcategory: Drugs Source of recall: Health Canada Audience: Healthcare Professionals

Archived – Medication Errors Involving Reminyl and Amaryl – Janssen-Ortho Inc. and Aventis Pharma Inc.

...® was incorrectly dispensed, leading to various adverse events including severe hypoglycemia. There were two reports of death. To the Companies' knowledge all reports have originated in the U.S.; we are not aware of any reports of medication errors in Canada to date. There have been prescriptions incorrectly written, interpreted, labeled or filled due to the similarity

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: